CIPDB › China Industry › Chemicals › Pharmaceutical Intermediate
Best Melanotan II Peptide Mt 21
Pharmaceutical IntermediateMt 2Peptide Mt 2
Xi'an Sase Biotechnology Co., Ltd
Preview:
Product DescriptionBest Melanotan II Peptide Mt 2Product DescriptionProduct DetailsProduct NameMelanotan IIAppearanceWhite powderCAS121062-08-6MFC50H69N15O9MW1024.17796Characterization of Melanotan II (CAS: 121062-08-6)Melanotan II, a synthetic cyclic heptapeptide with the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, has a molecular formula of C50H68N14O10 and a molecular weight of 1024.2 g/mol. This lyophilized white powder exhibits high solubility in water (>50 mg/mL) and acetic acid solutions but is insoluble in nonpolar solvents. The peptide features a disulfide bridge between Cys residues (in analogs) or lactam cyclization in this variant, conferring structural rigidity and protease resistance. Characterization by HPLC-MS shows >95% purity with a retention time of 12.3 minutes (C18 column, 0.1% TFA/ gradient), while CD spectroscopy confirms its α-helical secondary structure in physiological buffers. Stability studies indicate 24-month integrity at -20°C when protected from light and moisture, with degradation products (e.g., oxidized Trp or deamidated Asp) limited to <2% under accelerated conditions (40°C/75% RH for 3 months). Its pharmacokinetic profile includes subcutaneous bioavailability of 80-90% and a plasma half-life of 2-4 hours in humans, with renal clearance as the primary elimination route.Application&FunctionFunction and Applications of Melanotan IIMelanotan II functions as a non-selective melanocortin receptor agonist (MC1R/MC3R/MC4R/MC5R), mimicking α-MSH to induce skin pigmentation via melanocyte stimulation. Clinically, it demonstrates dose-dependent melanogenesis (tanning effects within 1-2 weeks of administration) and was investigated for erythropoietic protoporphyria to reduce photosensitivity. Off-label uses include libido enhancement through MC4R-mediated hypothalamic pathways and appetite suppression (reducing caloric intake by 20-30% in trials). The peptide shows potential in erectile dysfunction therapy, with 60-70% efficacy in non-responders to PDE5 inhibitors, though unregulated formulations raise safety concerns. Research explores its neuroprotective effects in Parkinson's models via MC4R activation and anti-inflammatory actions in sepsis. Regulatory status varies—while never FDA-approved, compounded versions persist in cosmetic markets, necessitating purity verification (HPLC-UV/MS) to exclude contaminants like β-MSH analogs. Dosing typically ranges from 0.025-0.5 mg/kg/day, though side effects (nausea, flushing) limit tolerability. Emerging studies investigate its metabolic benefits in obesity and wound healing acceleration, though controlled clinical data remain sparse.Specification
Purchasing Agent
Note: Send your message to supplier or manufacturer.
Welcome to our Professional and comprehensive procurement services...